IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.590
-0.010 (-0.63%)
At close: May 13, 2026, 4:00 PM EDT
1.650
+0.060 (3.77%)
After-hours: May 13, 2026, 6:25 PM EDT
IN8bio Employees
IN8bio had 17 employees as of December 31, 2025. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$1,116,471
Market Cap
15.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | -1 | -5.56% |
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Dec 31, 2021 | 19 | 5 | 35.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| NewcelX | 15 |
| Lipocine | 14 |
| Cocrystal Pharma | 10 |
| Genenta Science | 9 |
INAB News
- 6 days ago - IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 days ago - IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences - GlobeNewsWire
- 27 days ago - IN8bio Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators - Transcripts
- 5 weeks ago - IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026 - GlobeNewsWire
- 2 months ago - IN8bio Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - IN8bio to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - IN8bio appoints Kate Rochlin as president - TheFly